BRF1 and neoplasm: Aberrant complement pathway activation, as indicated by altered secretion of CFD in vitro and reduced levels of CFD and C7 in vivo, is mechanistically consistent with the observed altered immune infiltrates, including neutrophils and CD4 positive T cells, within the tumour microenvironment upon elevation of BRF1.